Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

"Patients with monocytic AML and no NPM1 mutation were ... correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study, Blood Cancer Discovery (2025).

The study highlights that patients with a subtype known as monocytic AML experience poorer outcomes ... Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia ...

An international study has uncovered why a widely used treatment for acute myeloid leukemia (AML ... patients with a certain type of AML, called "monocytic," had worse outcomes especially if ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia ... called “monocytic,” had worse outcomes ...

Learn about B-Cell Acute Lymphoblastic Leukemia (B-ALL), its symptoms, diagnosis, causes, and treatment options. Understand ...

Therapeutic efforts in acute myeloid leukemia (AML) face persistent challenges ... common in adult AML compared to pediatric AML, while monocytic differentiation patterns were more frequent ...

Hyperleukocytosis is often seen in monocytic variants and can be ... DIC is also observed in patients with AML, in particular, acute promyelocytic leukemia (APL or M3-AML). These patients are ...

CCR2 was highly expressed on malignant monocytes from AML patient samples, with cases of acute monocytic leukemia (M5) and acute myelomonocytic leukemia (M4), showing the highest levels of expression.

CCR2 was highly expressed on malignant monocytes from AML patient samples, with cases of acute monocytic leukemia (M5) and acute myelomonocytic leukemia (M4), showing the highest levels of expression.